A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Clinical trial NCT03368664 · TERMINATED
Trial details
- NCT number
- NCT03368664
- Sponsor
- Genzyme, a Sanofi Company
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-23
- Primary completion
- 2021-05-04
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.